Cite
HARVARD Citation
Grabowski, J. et al. (n.d.). 2022-RA-1192-ESGO NOGGO ov44 – PERCEPTION What is the role of immunotherapy in low grade ovarian cancer? A NOGGO phase II trial of pembrolizumab in combination with chemotherapy in recurrent low-grade serous ovarian cancer. International journal of gynecological cancer. p. A309. [Online].